Aldeyra Therapeutics Inc. (ALDX)
NASDAQ · Healthcare
Aldeyra Therapeutics Inc. EBITDA 2020–2025
Aldeyra Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Aldeyra Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -2.9 M, a 68.92% decrease year-over-year.
- Aldeyra Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -25.2 M.
- Aldeyra Therapeutics Inc. annual ebitda for 2025 was -31.7 M, a 40.96% decrease from 2024.
- Aldeyra Therapeutics Inc. annual ebitda for 2024 was -53.7 M, a 52.45% increase from 2023.
- Aldeyra Therapeutics Inc. annual ebitda for 2023 was -35.2 M, a 41.39% decrease from 2022.
- Aldeyra Therapeutics Inc. annual ebitda for 2022 was -60.1 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Aldeyra Therapeutics Inc. EBITDA — FAQ
Aldeyra Therapeutics Inc. (ALDX) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALDX's ebitda history?
The chart and table above show Aldeyra Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.